RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Staidson Beijing BioPharmaceuticals Co - Stock

Staidson Beijing BioPharmaceuticals Co Revenue 2024

Staidson Beijing BioPharmaceuticals Co Revenue

364.18 M CNY

Staidson Beijing BioPharmaceuticals Co Dividend yield

11.13 %

Ticker

300204.SZ

ISIN

CNE100001237

In 2024, Staidson Beijing BioPharmaceuticals Co's sales reached 364.18 M CNY, a -33.66% difference from the 548.99 M CNY sales recorded in the previous year.

The Staidson Beijing BioPharmaceuticals Co Revenue history

YEARREVENUE (undefined CNY)GROSS MARGIN (%)
20230.3679,52
20220.5581,46
20210.5880,07
20200.4381,75
20190.6687,77
20180.8190,72
20171.3994,45
20161.494,97
20151.2594,57
20141.0994,39
20130.8995,07
20120.5694,79
20110.2188,14
20100.1388,22
20090.0983,48
20080.0578,19

Staidson Beijing BioPharmaceuticals Co Aktienanalyse

What does Staidson Beijing BioPharmaceuticals Co do?

Staidson Beijing BioPharmaceuticals Co Ltd is a leading biopharmaceutical company based in Beijing, China. The company has a long history and a wide range of products and services that make it an important player in the biotechnology field. Staidson Beijing BioPharmaceuticals Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Staidson Beijing BioPharmaceuticals Co's Sales Figures

The sales figures of Staidson Beijing BioPharmaceuticals Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Staidson Beijing BioPharmaceuticals Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Staidson Beijing BioPharmaceuticals Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Staidson Beijing BioPharmaceuticals Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Staidson Beijing BioPharmaceuticals Co Stock

How much revenue did Staidson Beijing BioPharmaceuticals Co generate this year?

Staidson Beijing BioPharmaceuticals Co has achieved a revenue of 364.18 M CNY this year.

How much was the turnover of the company Staidson Beijing BioPharmaceuticals Co compared to the previous year?

The revenue of Staidson Beijing BioPharmaceuticals Co has increased by -33.66% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Staidson Beijing BioPharmaceuticals Co?

The revenue of Staidson Beijing BioPharmaceuticals Co is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Staidson Beijing BioPharmaceuticals Co measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Staidson Beijing BioPharmaceuticals Co so important for investors?

The revenue of Staidson Beijing BioPharmaceuticals Co is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Staidson Beijing BioPharmaceuticals Co pay?

Over the past 12 months, Staidson Beijing BioPharmaceuticals Co paid a dividend of 0.67 CNY . This corresponds to a dividend yield of about 11.13 %. For the coming 12 months, Staidson Beijing BioPharmaceuticals Co is expected to pay a dividend of 0 CNY.

What is the dividend yield of Staidson Beijing BioPharmaceuticals Co?

The current dividend yield of Staidson Beijing BioPharmaceuticals Co is 11.13 %.

When does Staidson Beijing BioPharmaceuticals Co pay dividends?

Staidson Beijing BioPharmaceuticals Co pays a quarterly dividend. This is distributed in the months of June, May, April, June.

How secure is the dividend of Staidson Beijing BioPharmaceuticals Co?

Staidson Beijing BioPharmaceuticals Co paid dividends every year for the past 0 years.

What is the dividend of Staidson Beijing BioPharmaceuticals Co?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Staidson Beijing BioPharmaceuticals Co located?

Staidson Beijing BioPharmaceuticals Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Staidson Beijing BioPharmaceuticals Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Staidson Beijing BioPharmaceuticals Co from 5/17/2019 amounting to 0.668 CNY, you needed to have the stock in your portfolio before the ex-date on 5/17/2019.

When did Staidson Beijing BioPharmaceuticals Co pay the last dividend?

The last dividend was paid out on 5/17/2019.

What was the dividend of Staidson Beijing BioPharmaceuticals Co in the year 2023?

In the year 2023, Staidson Beijing BioPharmaceuticals Co distributed 0 CNY as dividends.

In which currency does Staidson Beijing BioPharmaceuticals Co pay out the dividend?

The dividends of Staidson Beijing BioPharmaceuticals Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Staidson Beijing BioPharmaceuticals Co

Our stock analysis for Staidson Beijing BioPharmaceuticals Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Staidson Beijing BioPharmaceuticals Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.